Systemic cytotoxic and biologic therapies for colorectal cancer liver metastases: expert consensus statement  by Clary, Bryan M. et al.
COMMENTARY
Systemic cytotoxic and biologic therapies for colorectal cancer liver
metastases: expert consensus statement
Bryan M. Clary1, Axel Grothey2, Scott Kopetz3 & Robert D. W. Marsh4
1Department of Surgery, Duke University Medical Center, Durham, NC, USA, 2Department of Medicine, Mayo Clinic, Rochester, MN, USA, 3Department of
Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA and 4Department of Medicine, North Shore University Health
System, Chicago, IL, USA
Correspondence
Bryan M. Clary, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA. Tel: +1 919 684 6553.
Fax: +1 919 681 7508. E-mail: bryan.clary@duke.edu
The past 10 to 15 years have seen a great deal of excitement in the
field of metastatic colorectal cancer and, in particular, in the man-
agement of hepatic metastases. In addition to ongoing improve-
ments in perioperative management, ablative therapies and
imaging techniques, the introduction of new cytotoxic and tar-
geted systemic therapies has created wider treatment opportuni-
ties. With the improved outcomes of systemic chemotherapy
come additional complexities that are yet to be fully resolved (and
probably will not be as the field continues to evolve). The most
relevant questions in the current environment refer to the value
and appropriate timing of adjunctive systemic therapies in con-
junction with hepatectomy, and to strategies to optimize the
outcomes of systemic therapies in patients with advanced unre-
sectable disease. The potential impact of these therapies on the
histology and function of the liver in patients who may be candi-
dates for partial hepatectomy should be carefully considered and
understood. The nature and complexities of these issues require
close collaboration among hepatic surgeons and medical oncolo-
gists, as well as other members of the global treatment team,
including radiation oncologists and general and colorectal
surgeons.
In this issue of HPB, Schwarz et al.1 present readers with an
important summary of a consensus conference session that aimed
to clarify the roles of systemic therapies in patients with, respec-
tively, unresectable and resectable hepatic metastases. Specific
questions addressed by the panel referred to the value of adjuvant
peri-hepatectomy therapy, the optimization of cytotoxic thera-
pies, the roles of targeted therapies, and the potential hepatotox-
icities of these therapies. This session appropriately brought
together surgeons, medical oncologists and pathologists, all
of whom contributed to the construction of the consensus
statement.
Prior to discussing specific scenarios, it should be emphasized
that one of the most fundamental principles in selecting the
optimal type and sequence of therapies is that the goals of treat-
ment must be clearly established. For example, it should be deter-
mined beforehand whether the disease in the liver is considered
resectable or may be rendered so by successful therapy, or whether
it is never going to be operable for possible cure. The terminology
used should also be clarified because the terms ‘preoperative’,
‘perioperative’ and ‘postoperative’ all mean different things and
should not be used interchangeably. For patients with resectable
disease, the authors of the consensus statement declare that peri-
operative FOLFOX [folinic acid (leucovorin), fluorouracil (5-FU),
oxaliplatin] (i.e. delivered pre- and post-hepatectomy) should be
regarded as the reference treatment as findings in previous adju-
vant trials of postoperative chemotherapy did not show differ-
ences in outcomes of statistical significance. For many within the
field, this is likely to be contentious because the European Organi-
zation for Research and Treatment of Cancer (EORTC) 40983
trial, reported by Nordlinger and colleagues,1 showed negative
outcomes from an intent-to-treat perspective (in enrolled
patients) in that it demonstrated an increase in post-hepatectomy
morbidity in patients receiving pre-hepatectomy chemotherapy.
At the consensus conference, Dr Nordlinger presented data from a
more recent analysis of EORTC 40983, demonstrating significance
from an intent-to-treat perspective. It should be noted that this
trial does not resolve the issue of whether peri- or postoperative
chemotherapy is more effective, but only compares perioperative
treatment with none. Therefore, even if this updated experience is
disseminated in a peer-reviewed manner, some individuals will
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continue to regard post-hepatectomy systemic approaches as gen-
erally equivalent in easily resectable patients in whom tumour
shrinkage is not deemed beneficial. In recognition of these issues,
the consensus statement is supportive of postoperative systemic
therapy when pre-hepatectomy chemotherapy has been omitted,
but recognizes that Level I evidence for this approach does not
exist. As prognostic factors for early recurrence and progression,
the prior administration of adjuvant chemotherapy following
initial tumour resection and a short lead time to the development
of metachronous colorectal liver metastasis will need to be
weighed in this decision. Based on outcomes of using FOLFIRI
[folinic acid (leucovorin), 5-FU, irinotecan] as an adjuvant for
primary colorectal cancer2 and in the context of a randomized
trial comparing the use of adjuvant FOLFIRI with that of 5-FU in
post-hepatectomy patients with metastatic disease who failed to
demonstrate a benefit,3 the authors of the consensus statement do
not recommend FOLFIRI. The proper role of targeted therapies in
the adjuvant treatment of these patients is unclear, although it is
common practice for medical oncologists to include bevacizumab
with preoperative FOLFOX (omitting it in the cycle immediately
prior to hepatectomy). Published data suggesting that the hepa-
totoxicity of FOLFOX is ameliorated by the inclusion of bevaci-
zumab, together with evidence of its benefits in unresectable
patients with metastatic disease, make it difficult to argue against
its inclusion.4 Finally, response criteria certainly need to be clari-
fied and standardized, as radiologic response and pathologic
response may not be concordant and their incorrect interpreta-
tion may lead to suboptimal decisions regarding subsequent
therapy.
In addressing the role of systemic agents, including targeted
therapies, in unresectable patients, the consensus team impor-
tantly focuses on the need to establish the goals of therapy prior to
selecting a treatment regimen. Specifically, is treatment aimed at
downsizing the tumour to provide a reasonable possibility of
resection or is it intended to provide a non-curative or even pal-
liative approach? In recognition of the current literature, the con-
sensus statement allows for significant flexibility in the choice of
systemic regimens. For patients in whom there is a reasonable
possibility of downsizing to a point at which resection is feasible,
the consideration of hepatic and general toxicity is paramount.
This should be weighed against response rate expectations and
according to the minimum number of treatment cycles necessary
to achieve the intended treatment goals. Specifically, the use of
FOLFIRI and FOLFOXIRI, which may have more significant tox-
icity profiles, should be carefully considered in these potentially
resectable patients, especially in those in whom an extended dura-
tion of therapy (>4 months) may be required.5 The addition of
anti-vascular endothelial growth factor (anti-VEGF) or anti-
epidermal growth factor receptor (anti-EGFR) targeted agents to
first- and second-line cytotoxic backbones is highly encouraged by
the consensus group and is generally supported by improvements
in survival and response rates reported in the literature,6,7 whereas
anti-EGF targeted therapy alone may be reasonable within third-
line treatment. Conversely, data from the PanitumumabAdvanced
Colorectal Cancer Evaluation (PACCE)8 and CAIRO-29 studies
indicate that a combination of current anti-VEGF and anti-EGF
agents should not be used. The authors of the consensus statement
also address the limitations of capecitibine, both in combination
with irinotecan and alone, in patients in whom prior regimens
containing 5-FU have failed. This drug remains a reasonable alter-
native in combination with oxaliplatin10 or as a single agent when
5-FU has not previously failed.
The consensus group has appropriately laid foundations for the
acceptable utilization of systemic therapies in patients with
hepatic colorectal metastases. It is clear from these guidelines that
significant questions relating to the optimization of systemic regi-
mens and the appropriate timing of multimodal therapy in resect-
able patients persist. There has been a general plateau in the
evolution of cytotoxic therapies and targeted pathways (VEGF
and EGF) such that the past decade has accommodated the study
of how the delivery of these existing strategies might be optimized
and their roles in primary and metastatic disease better under-
stood. Further meaningful improvements depend on the identifi-
cation and development of new targets or agents that are more
effective against current targets. In this regard, regorafenib11 and
aflibercept12 are of definite interest. In addition, it is hoped that as
the biology of these tumours is further elucidated, and molecular
abnormalities are identified, a much more rational and targeted
approach to the choice and sequencing of therapy will become
possible. Finally, the consensus statement does not specifically
address the integration of alternative strategies, such as liver-
directed therapy with intra-arterial chemotherapy, chemoemboli-
zation, yttrium-90 or radiofrequency ablation, with systemic
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